Xilio TherapeuticsXLO
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 35 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, unchanged from Q4 2024. 6 opened new positions and 6 sold out. The largest holders were Gilead Sciences, Inc. ($6.6M), Bain Capital Life Sciences Investors, LLC ($3.3M) and Merck & Co., Inc. ($1.1M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $220K |
| Exits | 6 | $3.2M |
All 13F filers, Q4 2024 → Q1 2025: 823,257 shares bought and 4,150,406 shares sold, net −3,327,149 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Gilead Sciences, Inc. | 0.56% | No change | 9,105,451 | $6.6M |
| Bain Capital Life Sciences Investors, LLC | 0.49% | No change | 4,566,817 | $3.3M |
| Merck & Co., Inc. | 0.65% | No change | 1,483,758 | $1.1M |
| Takeda Pharmaceutical Co. Ltd. | 6.59% | No change | 1,475,121 | $1.1M |
| Morgan Stanley | 0.00% | Add +15.4% | 1,155,838 | $837K |
| Vanguard Group Inc. | 0.00% | Add +25.8% | 1,135,716 | $822K |
| FMR LLC | 0.00% | Reduce -36.7% | 884,035 | $640K |
| AJU IB Investment Co., Ltd. | 0.58% | No change | 667,742 | $484K |
| Geode Capital Management, LLC | 0.00% | Add +5.8% | 379,016 | $275K |
| Balyasny Asset Management L.P. | 0.00% | Reduce -25.9% | 254,346 | $184K |
| Trustees of Columbia University in the City of New York | 0.03% | No change | 249,635 | $181K |
| Renaissance Technologies | 0.00% | Reduce -40.1% | 177,700 | $129K |
| UBS Group AG | 0.00% | Reduce -34.6% | 163,101 | $118K |
| Avantax Planning Partners, Inc. | 0.00% | New | 150,399 | $109K |
| Two Sigma Investments, LP | 0.00% | Add +676.7% | 84,068 | $61K |
| BlackRock, Inc. | 0.00% | Reduce -1.8% | 74,700 | $54K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 71,081 | $51K |
| Northern Trust Corp. | 0.00% | Add +69.9% | 66,609 | $48K |
| Millennium Management | 0.00% | New | 51,110 | $37K |
| SevenBridge Financial Group, LLC | 0.01% | Add +12.2% | 46,000 | $34K |
| Aptus Capital Advisors, LLC | 0.00% | Add +12.2% | 46,000 | $33K |
| State Street Corp. | 0.00% | No change | 43,390 | $31K |
| Scientech Research LLC | 0.01% | New | 42,546 | $31K |
| ADAR1 Capital Management, LLC | 0.01% | New | 40,000 | $29K |
| Raymond James Financial Inc. | 0.00% | Reduce -32.2% | 33,961 | $25K |
| Mariner, LLC | 0.00% | No change | 25,000 | $18K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 20,000 | $14K |
| Dunhill Financial, LLC | 0.00% | New | 10,274 | $7K |
| Investors Asset Management of Georgia Inc. /Ga/ | 0.00% | New | 10,000 | $7K |
| Pinnacle Financial Group, LLC / IL | 0.00% | No change | 10,000 | $7K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 3,300 | $2K |
| Key Financial Inc | 0.00% | No change | 830 | $601 |
| Private Wealth Management Group, LLC | 0.00% | No change | 310 | $225 |
| Bank of America Corp. | 0.00% | Add +9.4% | 290 | $210 |
| JPMorgan Chase & Co. | 0.00% | Reduce -6.1% | 62 | $45 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.